Emma Cortez
Family · Tulare, CANPI 1548978745
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 145 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by AstraZeneca at 34.0% of the total. 2025 is the largest year on record at $2,053, more than ten times the $19 reported in 2022. Among family clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 145 payments — averaging $41.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Novo Nordisk$986
- Lilly USA, LLC$907
- AbbVie$514
- GSK$403
- Idorsia Pharmaceuticals US Inc$232
- plus $910 from 12 others
What the payments were for
- Food & beverage$5,985100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 27 | $2,033 |
| Novo Nordisk | 33 | $986 |
| Lilly USA, LLC | 25 | $907 |
| AbbVie | 11 | $514 |
| GSK | 14 | $403 |
| Idorsia Pharmaceuticals US Inc | 8 | $232 |
| Amgen | 7 | $200 |
| Boehringer Ingelheim | 3 | $143 |
| Braeburn Inc. | 1 | $128 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $125 |
| Mylan Specialty L.p. | 5 | $99 |
| Exact Sciences | 2 | $54 |
| Dexcom, Inc. | 1 | $41 |
| Pfizer | 2 | $34 |
| Cranial Technologies, Inc | 2 | $33 |
| Agile Therapeutics, Inc. | 1 | $20 |
| Organon | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,985 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 109 | $107,573 |
| RybelsusSemaglutide | 51 | $49,198 |
| FarxigaDapagliflozin Propanediol | 55 | $45,409 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 49 | $36,257 |
| JardianceEmpagliflozin | 27 | $21,348 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 30 | $18,523 |
| MounjaroTirzepatide | 15 | $15,462 |
| Repatha SureclickEvolocumab | 17 | $12,030 |
| EliquisApixaban | 19 | $11,182 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $2,814 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 74 | $1,330 |
| Levothyroxine Sodium | 124 | $1,262 |
| Gabapentin | 80 | $810 |
| Atorvastatin Calcium | 139 | $678 |
| Azelastine Hcl | 40 | $630 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $986 | $156,771160 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $2,033 | $63,93185 claims |
| GSKTrelegy Ellipta | $403 | $36,25749 claims |
| Boehringer IngelheimJardiance | $143 | $21,34827 claims |
| Lilly USA, LLCMounjaro | $907 | $15,46215 claims |
| PfizerEliquis | $34 | $11,18219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.
Other family in Tulare
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Erin DwyerSan Diego$189K
- Phyllis CasonLos Angeles$187K
- Gabriel SchwartzSan Francisco$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.